Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on January 10, 2020. The report details the results of a special meeting of stockholders held on the same date, which was reconvened from a meeting originally scheduled for December 12, 2019.
Key Financial Metrics
The filing does not provide specific financial data regarding revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and capital structure actions.
Material Changes
Stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock. The approved ratio is between 1-for-2 and 1-for-70, with the exact ratio and effective time to be determined by the Board of Directors.
- Shares Outstanding (Record Date): 36,818,956 shares as of November 19, 2019.
- Shares Present at Meeting: 20,424,055 shares.
- Votes For: 18,643,914
- Votes Against: 1,702,383
- Abstentions: 77,758
- Broker Non-Votes: None
Guidance, Outlook, and Risks
Management is taking steps to implement the reverse stock split. The specific ratio and effective date will be disclosed in a separate Form 8-K filing. The filing does not contain forward-looking guidance on financial performance, operational risks, or contingencies beyond the implementation of the stock split.
Investor Verification Checklist
- Verify the exact reverse stock split ratio and effective date in the subsequent Form 8-K filing.
- Confirm the impact of the reverse split on the number of shares held and the adjusted share price.
- Review the Definitive Proxy Statement (Schedule 14A) filed on November 22, 2019, for detailed rationale regarding the capital structure change.